YTHDF2は,B細胞悪性腫瘍におけるATP合成と免疫回避を促進する
Zhenhua Chen1, Chengwu Zeng2, Lu Yang1
1Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA; Center for RNA Biology and Therapeutics, City of Hope Beckman Research Institute, Duarte, CA 91010, USA.
Cell
|December 18, 2024
まとめ
YTHDF2タンパク質は,ATPの合成を促進し,免疫回避を促進することによって,B細胞の悪性腫瘍を駆動します. YTHDF2を標的とした治療は,B細胞がんにおけるキメリック抗原受容体 (CAR) - T細胞治療の有効性を改善する可能性がある.
科学分野:
- 腫瘍学
- 分子生物学
- 免疫学
背景:
- 化学抗原受容体 (CAR) -T細胞治療は,B細胞悪性腫瘍に対して有望であるが,抗原脱出によって制限されている.
- 悪性B細胞の成長とATP合成を支えるメカニズムは完全に理解されていません.
研究 の 目的:
- B細胞悪性腫瘍におけるYTHDF2の役割とその免疫療法への影響を調査する.
- YTHDF2ががんの進行と免疫回避に影響を与える分子メカニズムを解明する.
主な方法:
- B細胞の悪性腫瘍におけるYTHDF2発現の分析
- YTHDF2のm5Cおよびm6A変異のための二重RNA読者としての機能を調査する.
- 臨床前モデルのYTHDF2抑制の治療の可能性を評価する.
主要な成果:
- YTHDF2の過剰発現はB細胞の変容と腫瘍形成を促す
- YTHDF2は,PABPC1 (m5Cリーダ) による特定のmRNAの安定化によってATP合成を強化する.
- YTHDF2は,他のmRNA (m6Aリーダー) を不安定化することによって,免疫回避を促進します.
結論:
- YTHDF2は,B細胞悪性腫瘍におけるエネルギー代謝と免疫回避の重要な調節剤である.
- YTHDF2を小さな分子で標的にすることで,腫瘍の成長を抑制し,CAR- T細胞治療の有効性を高めます.
関連する概念動画
Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
B Cell Activation and Differentiation
1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K
T Cell Types and Functions
947
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
947
Cytotoxic T Cells-mediated Immune Response
844
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
844
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
T Cell Activation and Clonal Selection
655
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
655


